Omega-3 Supplements: A Pharmacist's Complete Guide — EPA, DHA, and Which Formula Is Right for You

Dai Tran, PharmD, MBA, B.S.

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist

Clinical Insights Series • APhA Immunization Certified • 10+ Years Clinical Experience

The Clinical Question

What does peer-reviewed human evidence establish for EPA and DHA supplementation — for cardiovascular outcomes, triglyceride lowering, inflammatory markers, cognitive function, and eye health — and how does formulation (triglyceride vs. ethyl ester form, dose, EPA:DHA ratio) affect clinical relevance?

Bottom Line Up Front

EPA and DHA are the two principal marine omega-3 fatty acids with distinct biological roles. The evidence base varies substantially by outcome:

• Triglyceride lowering — STRONG: dose-dependent, well-replicated across 90 RCTs; most consistent at ≥2 g/day EPA+DHA.
• Major cardiovascular outcomes — MIXED / FORMULATION- AND DOSE-DEPENDENT: modest benefit in some large meta-analyses; null in others; pharmacological pure-EPA trials are not generalizable to standard supplemental doses.
• Inflammatory biomarkers — MODERATE / SUPPORTIVE: significant reductions in CRP, TNF-α, IL-6 across umbrella meta-analyses; EPA:DHA ratio and dose influence magnitude.
• Cognition — MODEST / POPULATION-DEPENDENT: statistically significant but small pooled effect; results heterogeneous across populations and outcomes.
• AMD prevention — NOT ESTABLISHED: the major RCT (AREDS2) did not find a significant benefit from adding DHA+EPA to the standard AREDS formulation.
• TG-form bioavailability advantage — ESTABLISHED pharmacokinetically; clinical-outcome superiority vs. ethyl ester form NOT established in head-to-head outcome trials.
• Atrial fibrillation risk at higher doses — IMPORTANT SAFETY SIGNAL: dose-dependent increase in AF risk documented across 7 RCTs/81,210 participants.

No finished supplement product sold at Khang Pharmacy has been specifically tested in an independent clinical outcome trial.

What Human Studies Show

1. Triglyceride Lowering — STRONG

• SYSTEMATIC REVIEW / META-ANALYSIS Wang et al., 2023 (PMID: 37264945) — 90-RCT dose-response meta-analysis: Continuous dose-response meta-analysis of 90 RCTs (72,598 participants) evaluating EPA, DHA, or both. Found an approximately linear dose-response relationship between omega-3 intake and triglyceride lowering; the effect was most pronounced in individuals with hyperlipidemia or overweight/obesity at doses above 2 g/day EPA+DHA. This is the primary evidence base for triglyceride lowering as omega-3’s most consistently established clinical benefit.

2. Major Cardiovascular Outcomes — MIXED

• SYSTEMATIC REVIEW / META-ANALYSIS Hu et al., 2019 (PMID: 31567003) — 13-RCT cardiovascular meta-analysis: Meta-analysis of 13 RCTs (127,477 participants). Marine omega-3 supplementation was associated with modest reductions in MI (RR 0.92), CHD death (RR 0.92), total CHD (RR 0.95), cardiovascular death (RR 0.93), and total CVD (RR 0.97). Effect sizes are modest and driven substantially by higher-dose trials.
• CRITICAL APPRAISAL Aung et al., 2018 (PMID: 29387889) — Null cardiovascular meta-analysis: Meta-analysis of 10 large trials (77,917 participants). Did not find statistically significant associations between omega-3 supplementation and CHD death, nonfatal MI, overall CHD, stroke, or total major vascular events. The Hu and Aung meta-analyses together illustrate that cardiovascular outcome evidence for omega-3s is genuinely mixed and population- and dose-dependent — not uniformly positive.
• HUMAN RCT REDUCE-IT — Bhatt et al., 2019 (PMID: 30415628): Randomized trial; n=8,179 statin-treated patients with TG 135–499 mg/dL; icosapent ethyl (prescription purified EPA) 4 g/day vs. mineral oil placebo; median 4.9 years. Primary composite cardiovascular endpoint: 17.2% vs. 22.0% (HR 0.75). AF/flutter hospitalization was 3.1% vs. 2.1% in the EPA arm. Critical context: pharmacological dose of prescription purified EPA — not a standard fish oil supplement. The mineral oil control has been criticized as potentially pro-inflammatory, which may have inflated the apparent treatment effect. Results cannot be extrapolated to supplemental mixed EPA/DHA doses.
• CRITICAL APPRAISAL STRENGTH — Nicholls et al., 2020 (PMID: 33190147): Randomized trial; n=13,078; high-dose EPA+DHA carboxylic acid formulation 4 g/day vs. corn oil; primary endpoint HR 0.99; stopped early for futility. The discordance between REDUCE-IT (pure EPA vs. mineral oil, benefit) and STRENGTH (EPA+DHA vs. corn oil, null) is an important and unresolved feature of the omega-3 cardiovascular evidence landscape.

3. Formulation: Triglyceride Form vs. Ethyl Ester Form — ESTABLISHED pharmacokinetically; clinical superiority NOT established

• HUMAN RCT Neubronner et al., 2011 (PMID: 21063431) — TG vs. EE, 6-month randomized trial: Randomized supplementation using identical EPA+DHA doses over 6 months. Triacylglyceride form produced a faster and greater Omega-3 Index increase compared to ethyl esters. Specific preparations; results reflect a pharmacokinetic endpoint, not a clinical outcome comparison.
• HUMAN STUDY Dyerberg et al., 2010 (PMID: 20638827) — Direct formulation bioavailability study: 72 volunteers receiving approximately 3.3 g EPA+DHA/day for 2 weeks. Relative to natural fish oil: re-esterified TG form 124% relative bioavailability; ethyl ester 73%; free fatty acid 91%. Specific proprietary preparations; magnitude of difference varies across preparations and conditions. Whether pharmacokinetic advantage translates to superior clinical outcomes has not been established in head-to-head outcome trials.

4. Inflammatory Biomarkers — MODERATE / SUPPORTIVE

• SYSTEMATIC REVIEW / META-ANALYSIS PMID: 35914448 — Umbrella meta-analysis, 32 meta-analyses: Umbrella meta-analysis incorporating 32 meta-analyses of RCTs. Omega-3 fatty acid supplementation produced statistically significant reductions in CRP, TNF-α, and IL-6. This is the broadest and most methodologically comprehensive inflammation evidence available for omega-3s.
• SYSTEMATIC REVIEW / META-ANALYSIS Khabir et al., 2026 (PMID: 41568426) — EPA:DHA ratio, dose, and inflammation; 96 clinical trials: Systematic review and meta-analysis of 96 clinical trials. Found reductions in CRP, TNF-α, and IL-6; most consistent inflammatory-marker reductions at approximately 1–3 g/day EPA+DHA. Regarding the EPA:DHA ratio, the meta-analysis found that ratios below 1.0 (DHA-dominant) produced the greatest cytokine reductions, while ratios ≥1.0 (EPA-dominant or balanced) more strongly increased blood EPA:DHA ratio and lowered arachidonic acid. These are distinct and non-interchangeable outcomes; EPA-dominant ratios were not shown to be superior for inflammatory cytokine reduction. Disclosure: one author (Fabrizio Camponovo) is affiliated with Soho Flordis International Switzerland SA, a dietary supplement company; readers should interpret findings with this commercial affiliation in mind.

5. Cognitive Function — MODEST / POPULATION-DEPENDENT

• OVERVIEW OF SYSTEMATIC REVIEWS / META-ANALYSIS Barros et al., 2025 (PMID: 41010527) — Overview of 9 systematic reviews; 26,881 participants: Overview of systematic reviews incorporating 9 systematic reviews, 14 RCTs, and 26,881 participants aged ≥40 years. Pooled analysis found a statistically significant but small improvement in MMSE (effect size 0.16; 95% CI 0.01–0.32; I² 42.8%). Evidence supports modest cognitive benefit in selected populations with non-dementia or mild cognitive impairment; the magnitude is small and results remain heterogeneous across cognitive domains and populations.

6. Eye Health (DHA) — NOT ESTABLISHED for AMD prevention by supplementation

• HUMAN STUDY Structural biology context: DHA is the principal structural lipid of the photoreceptor outer segment and retinal membranes, constituting up to 50% of total fatty acids in retinal rod photoreceptors. Its structural role in visual system development and maintenance is established. Whether supplementation independently improves clinical eye outcomes requires evaluation in outcome trials.
• CRITICAL APPRAISAL AREDS2 Research Group, 2013 (PMID: 23644932): Multicenter randomized clinical trial; n=4,203; DHA 350 mg + EPA 650 mg vs. control; median follow-up 5 years. Adding DHA+EPA to the standard AREDS formulation did not significantly reduce progression to advanced AMD. This is the most important clinical outcome trial for omega-3s and eye health — a null result that the article represents transparently.

7. Atrial Fibrillation Safety Signal — IMPORTANT SAFETY SIGNAL, DOSE-DEPENDENT

• SYSTEMATIC REVIEW / META-ANALYSIS Gencer et al., 2021 (PMID: 34612056) — AF meta-analysis, 7 RCTs, 81,210 participants: Systematic review and meta-analysis of 7 large RCTs (81,210 participants) from cardiovascular outcome trials. Overall HR for AF: 1.25 (95% CI 1.07–1.46). Dose-response relationship observed: at >1 g/day HR 1.49; at ≤1 g/day HR 1.12. Patients with a history of atrial fibrillation or those on higher-dose omega-3 regimens should discuss this risk signal with their healthcare provider.

Known Limitations in the Evidence Base

• REDUCE-IT used prescription purified EPA at 4 g/day vs. a criticized mineral oil control; results cannot be extrapolated to standard supplemental mixed EPA/DHA doses
• STRENGTH (n=13,078, EPA+DHA 4 g/day) found no cardiovascular benefit; its discordance with REDUCE-IT is unresolved
• The Hu and Aung cardiovascular meta-analyses reach different conclusions from overlapping trials — dose, population, and baseline TG substantially influence the direction of effect
• Bioavailability advantage of TG form vs. EE form is pharmacokinetically documented but clinical-outcome superiority has not been established in head-to-head outcome trials
• Cognitive benefits are statistically significant but small (MMSE effect size 0.16; I² 42.8%) and heterogeneous across populations and domains
• AREDS2 did not find a significant AMD benefit from adding DHA+EPA; DHA’s structural presence in the retina does not establish a supplementation benefit
• EPA:DHA ratio research (PMID: 41568426) found DHA-dominant ratios (<1.0) produced the greatest cytokine reductions; EPA-dominant ratios were not demonstrated to be superior for inflammatory cytokine endpoints
• Dose-dependent AF risk is documented (>1 g/day HR 1.49); patients at higher doses or with AF history should be counseled
• No clinical trial has specifically tested OmegaGenics® or Wiley’s Finest® as finished products

Safety & Drug Interactions

• Atrial fibrillation: A meta-analysis of 7 RCTs/81,210 participants (PMID: 34612056) found a dose-dependent increase in AF risk: overall HR 1.25 (95% CI 1.07–1.46); at >1 g/day HR 1.49; at ≤1 g/day HR 1.12. Patients with a history of AF or those considering higher-dose omega-3 supplementation should discuss this with their healthcare provider.
• Anticoagulants and antiplatelet agents: High-dose omega-3s (≥3 g/day) may have mild antiplatelet activity. If you take warfarin, aspirin, clopidogrel, or other anticoagulants, consult your pharmacist before starting omega-3 supplementation. INR monitoring may be warranted at initiation.
• Blood glucose: High-dose omega-3s may modestly affect fasting glucose in some individuals with diabetes. Routine monitoring is appropriate.
• Pregnancy and nursing: DHA is essential for fetal brain and retinal development. Consult your healthcare provider about appropriate omega-3 dosing; prenatal formulations are generally preferred over high-dose EPA-dominant supplements in this population.
• Generally well-tolerated: At supplemental doses, fish oil is well tolerated. Common adverse effects are GI (fishy aftertaste, eructation, loose stools); TG-form and enteric-coated formulas tend to be better tolerated.

About the Products We Carry

Khang Pharmacy carries omega-3 supplements evaluated for sourcing transparency, formulation quality, and manufacturing standards. Clinical results from the studies cited in this article cannot be assumed to apply to these finished products.

Metagenics OmegaGenics® 5-in-1 Fish Oil 1000 mg EPA-DHA

Pharmacist’s Note: As a PharmD, I discuss OmegaGenics® with patients seeking a high-dose, TG-form omega-3 with documented sourcing and contaminant testing. Its EPA-dominant ratio (710:290) is relevant to emerging EPA:DHA ratio research (PMID: 41568426), although that meta-analysis found that ratios below 1.0 produced the greatest cytokine reductions, while ratios ≥1.0 more strongly increased the blood EPA:DHA ratio and lowered arachidonic acid — these are distinct outcomes and EPA dominance was not shown to be superior for inflammatory cytokine reduction. At 1,000 mg EPA+DHA per softgel (2 softgels/day = 2,000 mg), this formula reaches the dose range where triglyceride-lowering evidence is most consistent. These ingredient-level findings cannot be assumed to apply to this finished product.

Wiley’s Finest® Omega-3 with K2 & D3 — 500 mg EPA & DHA

Pharmacist’s Note: As a PharmD, I discuss Wiley’s Finest® with patients who need K2 and D3 alongside omega-3 in a single convenient softgel. The ethyl ester form has lower relative bioavailability vs. TG form in pharmacokinetic studies, though the gap narrows when taken with food. At 500 mg EPA+DHA per softgel this is a lower-dose option that falls at the lower end of the dose range for consistent triglyceride-lowering evidence; patients with higher omega-3 clinical targets may need a higher-concentration formula.

Head-to-Head Comparison

Pharmacist’s Decision Framework

• For triglyceride support or cardiovascular goals at ≥1 g EPA+DHA/day: OmegaGenics® provides 1,000 mg EPA+DHA per softgel in TG form. Pharmacokinetic data supports higher absorption vs. EE form; outcome-trial superiority has not been established.
• If you also need K2 and D3: Wiley’s Finest® provides 500 mg EPA+DHA alongside MenaQ7® K2 and D3; useful for patients managing bone and cardiovascular goals with one product.
• If you take anticoagulants or antiplatelet agents: Consult your Khang Pharmacy pharmacist before starting omega-3 supplementation. High-dose EPA may have additive antiplatelet effects with warfarin and antiplatelet drugs.
• If you have a history of atrial fibrillation: Discuss the dose-dependent AF risk signal (PMID: 34612056; HR 1.49 at >1 g/day) with your healthcare provider before initiating higher-dose omega-3 supplementation.
• If you are pregnant or nursing: DHA is essential for fetal brain and retinal development. Speak with your healthcare provider; prenatal formulas are generally preferred over high-dose EPA-dominant supplements.
• Take with food: Omega-3 absorption improves significantly with a fat-containing meal for both TG and EE forms; the bioavailability gap between forms narrows under fed conditions.

Pharmacist’s Interpretation

As a PharmD, I discuss omega-3 supplementation in the context of each patient’s full health picture — cardiovascular risk factors, medications, diet, and realistic clinical goals. The strongest evidence is for triglyceride lowering at ≥2 g/day EPA+DHA; cardiovascular hard-endpoint data is genuinely mixed and I frame it that way rather than selectively citing positive trials. The AF safety signal is clinically important and I raise it proactively with patients considering >1 g/day. I do not represent OmegaGenics® or Wiley’s Finest® as clinically proven for specific outcomes — no independent outcome trial has tested either finished product. The ingredient-level evidence supports these formulas as reasonable approaches to omega-3 supplementation when quality, sourcing, and formulation characteristics are considered. Call us at (408) 622-8068 for a free pharmacist consultation.

Frequently Asked Questions

Q: How much EPA and DHA do I need daily?
A: Triglyceride-lowering evidence is most consistent at ≥2 g/day EPA+DHA. General wellness dosing of 500–1,000 mg/day is commonly used. Pharmacological trials used ≥4 g/day. Consult your healthcare provider for personalized dosing, especially with existing cardiovascular conditions.

Q: Should I take omega-3s with food?
A: Yes. Both TG-form and EE-form omega-3s absorb better with a fat-containing meal; the bioavailability gap between forms narrows considerably under fed conditions.

Q: Is TG form meaningfully better than ethyl ester?
A: Pharmacokinetic studies (PMID: 21063431; PMID: 20638827) document higher relative bioavailability for TG form. Whether this translates to superior clinical outcomes has not been established in head-to-head outcome trials. The difference is most relevant under fasted conditions and may be less significant when both are taken with food.

Q: Does omega-3 supplementation prevent macular degeneration?
A: The major RCT (AREDS2; PMID: 23644932; n=4,203; 5-year follow-up) found that adding DHA+EPA to the standard AREDS formulation did not significantly reduce progression to advanced AMD. DHA is structurally important in the retina, but supplementation has not been shown to prevent AMD.

Q: Can I take omega-3s on blood thinners?
A: High-dose omega-3s (≥3 g/day) may have mild antiplatelet activity. Consult your Khang Pharmacy pharmacist before starting omega-3 supplementation if you take warfarin, aspirin, clopidogrel, or other anticoagulants.

Q: What is the AF risk from omega-3 supplementation?
A: A meta-analysis of 7 RCTs/81,210 participants (PMID: 34612056) found an overall HR of 1.25 (95% CI 1.07–1.46) for AF, with a dose-dependent signal: HR 1.49 at >1 g/day; HR 1.12 at ≤1 g/day. Patients with a history of AF should discuss this risk with their healthcare provider.

Q: Are your products tested for mercury and heavy metals?
A: OmegaGenics® is manufacturer-reported tested for 200+ contaminants including heavy metals and microplastics. Wiley’s Finest® uses Wild Alaska Pollock from an MSC-certified fishery. Verify current certifications directly with manufacturers.

Selected Key Studies

1. SYSTEMATIC REVIEW / META-ANALYSIS Wang T, et al. Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2023. PMID: 37264945.
   90 RCTs, 72,598 participants; linear dose-response TG lowering; strongest at >2 g/day in hyperlipidemia/overweight. Primary TG reference.
2. SYSTEMATIC REVIEW / META-ANALYSIS Hu Y, Hu FB, Manson JE. Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127,477 Participants. J Am Heart Assoc. 2019;8:e013543. PMID: 31567003.
   Modest reductions in MI (RR 0.92), CHD death (RR 0.92), CVD death (RR 0.93); effect sizes driven by higher-dose trials.
3. CRITICAL APPRAISAL Aung T, et al. Associations of Omega-3 Fatty Acid Supplement Use with Cardiovascular Disease Risks. JAMA Cardiol. 2018;3:225–234. PMID: 29387889.
   10 large RCTs, 77,917 participants; no significant benefit for CHD death, nonfatal MI, total CHD, stroke, or major vascular events. Essential cardiovascular counterpoint.
4. HUMAN RCT Bhatt DL, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT). N Engl J Med. 2019;380:11–22. PMID: 30415628.
   n=8,179; pure EPA 4 g/day; primary endpoint HR 0.75; AF 3.1% vs. 2.1%. Pharmacological dose, criticized mineral oil control; not generalizable to supplemental doses.
5. CRITICAL APPRAISAL Nicholls SJ, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events (STRENGTH). JAMA. 2020;324:2268–2280. PMID: 33190147.
   n=13,078; EPA+DHA 4 g/day; primary endpoint HR 0.99; stopped for futility. Ideal counterbalance to REDUCE-IT.
6. HUMAN RCT Neubronner J, et al. Enhanced increase of omega-3 index in response to long-term n-3 fatty acid supplementation from triacylglycerides versus ethyl esters. Eur J Clin Nutr. 2011;65:247–254. PMID: 21063431.
   6-month randomized trial; TG form produced faster and greater Omega-3 Index increase vs. EE at identical doses.
7. HUMAN STUDY Dyerberg J, et al. Bioavailability of marine n-3 fatty acid formulations. Prostaglandins Leukot Essent Fatty Acids. 2010;83:137–141. PMID: 20638827.
   72 volunteers; re-esterified TG 124% relative bioavailability vs. EE 73% vs. FFA 91% (vs. natural fish oil baseline).
8. SYSTEMATIC REVIEW / META-ANALYSIS Efficacy of omega-3 fatty acid supplementation on inflammatory biomarkers: an umbrella meta-analysis. PMID: 35914448.
   32 meta-analyses included; significant reductions in CRP, TNF-α, IL-6. Broadest inflammation evidence base for omega-3s.
9. SYSTEMATIC REVIEW / META-ANALYSIS Khabir Z, et al. Role of the EPA:DHA dosing ratio in omega-3 supplements on blood fatty acid profiles and inflammation: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2026;66(20):3866–3887. PMID: 41568426.
   96 clinical trials; reductions in CRP, TNF-α, IL-6; ratios <1.0 (DHA-dominant) produced greatest cytokine reductions; ratios ≥1.0 most strongly increased blood EPA:DHA ratio and lowered arachidonic acid. Disclosure: one author affiliated with Soho Flordis International Switzerland SA.
10. OVERVIEW OF SYSTEMATIC REVIEWS / META-ANALYSIS Barros MI, et al. Omega-3 Polyunsaturated Fatty Acids and Cognitive Decline in Adults with Non-Dementia or Mild Cognitive Impairment: An Overview of Systematic Reviews. Nutrients. 2025;17(18):3002. PMID: 41010527.
    9 SRs, 14 RCTs, 26,881 participants ≥40 years; MMSE effect size 0.16 (95% CI 0.01–0.32; I² 42.8%); statistically significant but small; heterogeneous across domains.
11. CRITICAL APPRAISAL AREDS2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the AREDS2 randomized clinical trial. JAMA. 2013;309:2005–2015. PMID: 23644932.
    n=4,203; DHA 350 mg + EPA 650 mg; median 5 years; adding DHA+EPA to AREDS formulation did not significantly reduce progression to advanced AMD.
12. SYSTEMATIC REVIEW / META-ANALYSIS Gencer B, et al. Effect of Long-Term Marine ω-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. Circulation. 2021;144:1981–1990. PMID: 34612056.
    7 RCTs, 81,210 participants; overall AF HR 1.25 (95% CI 1.07–1.46); >1 g/day HR 1.49; ≤1 g/day HR 1.12; dose-response relationship established.

Reviewed by:

Dai Tran, PharmD, MBA, B.S. • View full bio →

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist

Khang Pharmacy | 2451 S King Rd., Ste A1, San Jose, CA 95122 | (408) 622-8068 | www.khangpharmacy.com